Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated to provide sufficient runway into late 2027 SAN DIEGO and SUZHOU, China, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced year-end unaudited cash and cash equivalen ...

Core Insights - Sanofi's amlitelimab drug has demonstrated its potential to treat eczema in patients aged 12 years and older through two late-phase studies [1] Group 1 - The drug's efficacy was confirmed in late-phase studies, indicating a significant advancement in eczema treatment options for adolescents and adults [1]

Core Insights - Amlitelimab shows promising results in treating moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older, supported by positive outcomes from two phase 3 studies, SHORE and COAST 2 [1][2] Study Results - In the SHORE study, amlitelimab met all primary and key secondary endpoints at Week 24, demonstrating significant efficacy compared to placebo [3][5] - The primary endpoint for SHORE was the proportion of patients achieving a validated investigator global assessment scale for AD (vIGA-AD) of 0 or 1, with a reduction from baseline score of ≥2 points [2][4] - In the COAST 2 study, amlitelimab met the primary endpoint for the US and US reference countries but did not achieve statistical significance for co-primary endpoints in the EU and EU reference countries [5][8] Efficacy Data - In the SHORE study, the proportion of patients achieving vIGA-AD 0/1 was 28.7% for Q4W dosing and 32.3% for Q12W dosing, both statistically significant [4] - The EASI-75 response rates were 48.1% for Q4W and 46.8% for Q12W, also showing statistical significance [4] - In the COAST 2 study, the vIGA-AD 0/1 rates were 25.3% for Q4W and 25.7% for Q12W, with EASI-75 rates of 41.8% and 40.5% respectively [9] Safety Profile - Amlitelimab was well-tolerated in both studies, with treatment-emergent adverse events (TEAEs) similar to placebo [12][13] - Common TEAEs in the SHORE study included nasopharyngitis (9.5% vs 12.5% in placebo) and upper respiratory tract infection (7.9% vs 4.4%) [12] - In the COAST 2 study, the most common TEAEs were nasopharyngitis (5.9% vs 7.4% in placebo) and upper respiratory tract infection (4.8% vs 4.0%) [13] Future Directions - Sanofi plans to move forward with global regulatory submissions for amlitelimab based on the totality of data from the studies [5] - Preliminary analysis from the ATLANTIS phase 2 study indicates continued improvements in skin clearance and disease severity beyond Week 24 [14][16] - Additional phase 3 studies, AQUA and ESTUARY, are expected to report results in H2 2026 [18]

In this articlePFENVOUS President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty ImagesDrug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0.Those are among the themes that dominated conversations last week as drugmakers of all sizes met with investors to map out their plans for 2026 and beyond at the annual JPMorgan Healthcare Conference in San Francisco. After geopolit ...

U.S. President Donald Trump speaks to members of the press before boarding Marine One on the South Lawn of the White House on Jan. 16, 2026 in Washington, DC.Tom Brenner | Getty ImagesU.S. President Donald Trump has threatened a rising wave of tariffs on several European allies, raising the alarm for industries and businesses across the region.Trump on Saturday pledged to impose 10% tariffs on the U.K., Denmark, Norway, Sweden, France, Germany, the Netherlands, and Finland by Feb. 1, ramping up his push to ...

Company Overview - Sanofi is a global healthcare leader engaged in the research, development, manufacturing, and marketing of pharmaceutical products, focusing on innovative solutions in vaccines, rare diseases, multiple sclerosis, oncology, immunology, and cardiovascular diseases [1] - The company competes with other pharmaceutical giants like Pfizer and GlaxoSmithKline [1] Recent Developments - Sanofi achieved a significant milestone with the approval of two innovative medicines, Myqorzo and Redemplo, by China's National Medical Products Administration, indicating a strong commitment to the Chinese market [3] - Myqorzo treats obstructive hypertrophic cardiomyopathy, while Redemplo targets triglyceride levels in patients with familial chylomicronemia syndrome [3] Stock Performance - The current stock price of Sanofi (SNY) on NASDAQ is $46.59, reflecting a decrease of approximately 1.86%, with a trading range from $46.49 to $47.03 [4] - Over the past year, the stock has seen a high of $60.12 and a low of $44.62, indicating some volatility [4] - Sanofi's market capitalization is approximately $113.5 billion, with a trading volume of 1,517,570 shares, reflecting a strong position in the pharmaceutical industry despite recent fluctuations [5] Analyst Ratings - Deutsche Bank maintained a "Buy" rating for Sanofi, with the stock trading at $46.63, but adjusted the price target from EUR 110 to EUR 105, indicating a more conservative outlook [2][6]

Recursion Pharmaceuticals FY Conference Summary Company Overview - Recursion Pharmaceuticals operates in the biotechnology sector, focusing on integrating AI and automation into drug discovery and development, differentiating itself from over 1,000 biotech companies by pursuing a balanced business model rather than a binary risk model [4][5] - The company has generated over 45 petabytes of proprietary data, which is a significant differentiator in its operations [5][6] Leadership Transition - A recent leadership transition occurred with Chris stepping down as CEO to become Chairman, succeeded by Najat Khan, who previously led R&D operations [7][10] - The mission and vision of the company remain unchanged, focusing on improving the probability of success in drug development [9][10] Cost Management and Efficiency - The company has implemented a 35% reduction in projected spending for 2024, amounting to over $200 million in cost savings [12] - Emphasis on operational discipline and cash management is a key focus under the new leadership [12][13] Market Dynamics - The biotechnology industry is evolving with a shift towards data-driven strategies, particularly in large pharmaceutical companies [14][15] - Recursion is positioned as a pioneer in utilizing AI to create and analyze data, addressing the vast untapped potential in the remaining 90% of biology [15][16] Data and Modeling Capabilities - Recursion has developed a unique in-house data generation capability, creating a consistent format for data that enhances its modeling systems [21][22] - The company emphasizes the importance of creating drug-like molecules that are manufacturable and cost-effective [24][25] Partnerships and Financials - Recursion has secured over $500 million from partnerships, with significant milestones achieved, particularly with Sanofi and Roche [6][28] - The company has favorable economics in its partnerships, with potential milestones and royalties structured to provide substantial revenue [30][31] Clinical Programs and Pipeline - The company is advancing several clinical programs, including REC-4881 for familial adenomatous polyposis (FAP), which has shown promising results in reducing polyp burden [34][36] - The REC-617 program is also highlighted, with multiple drugs expected to have important data points in the next 12-18 months [39][40] Regulatory Engagement - Positive discussions with the FDA are ongoing, with a focus on leveraging AI and data in regulatory processes [38] Cash Management and Operational Strategy - Recursion expects to end 2025 with $755 million in cash, providing a runway into 2027, with a focus on efficient cash use for program development [41][42] - The company employs an outcomes-based model to measure spending and resource allocation effectively [42][43] M&A Considerations - While Recursion does not need to pursue M&A, it remains open to opportunities that align with its platform and capabilities [49][51] Conclusion - Recursion Pharmaceuticals is at a pivotal point in its development, leveraging AI and data to drive innovation in drug discovery while maintaining a disciplined approach to cost management and operational efficiency [10][12][13]

Market Overview - Major European markets closed lower due to geopolitical tensions and uncertainty surrounding French budget negotiations, with investors taking profits from recent gains [1][2] - The pan-European Stoxx 600 edged down 0.03%, with the U.K.'s FTSE 100 down 0.04%, Germany's DAX down 0.22%, and France's CAC 40 down 0.65% [3] Company Performance - In the UK market, BAE Systems, Natwest Group, Smiths Group, Schroders, National Grid, Standard Chartered, British Land Company, and The Sage Group gained between 1.4% to 2.3% [4] - Conversely, Pearson, Metlen Energy & Metals, Entain, Antofagasta, Endeavour Mining, Glencore, Anglo American Plc., and Pershing Square Holdings lost between 2% to 4% [4] - Daimler Truck Holding reported a decline in 2025 sales, contributing to its stock decline [5] - Siemens Energy saw a significant increase of over 5%, while Zalando, RWE, and Fresenius Medical Care gained between 1.5% to 1.7% [6] Notable Transactions - Kloeckner & Co shares soared over 28% following Worthington Steel's announcement of a $2.4 billion acquisition of the German steel processor [6] French Market Insights - In the French market, Kering and Essilor closed down by 4.7% and 4%, respectively, while LVMH, Stellantis, TP, and Renault lost between 2.7% to 3.1% [6][7]

Summary of Molecular Partners FY Conference Call Company Overview - **Company Name**: Molecular Partners (NasdaqGS:MOLN) - **Focus**: Development of DARPin candidates, particularly in the field of radiotherapy - **Financial Position**: Over $100 million in cash (approximately CHF 93 million) available for investment in R&D [4][30] Key Industry Insights - **Biotech Sector Outlook**: Increased confidence in a turnaround for the biotech sector in 2026, following a challenging period [3] - **Radiotherapy Market**: Positive feedback and renewed interest in radiotherapy, highlighted by the successful IPO of Aktis Oncology [3] Core Product Focus - **Primary Candidate**: MP0712, a DLL3-targeted DARPin, is expected to drive value creation in the upcoming year [4][6] - **Pipeline Overview**: Emphasis on MP0712, with additional focus on MPO 317 and MPO 533, which are also in development [6][11] Product Development and Clinical Trials - **MPO 317**: Initially considered a dead program, it has been revived due to promising phase one data showing immune activation in colorectal carcinoma. A new trial will involve 75 patients across 11 centers in France, with results expected in 2027 [10][11] - **MPO 533**: A multispecific DARPin targeting acute myeloid leukemia (AML), designed to eradicate residual disease clones. The focus will be on low disease burden patients [11][12] Radiotherapy Mechanism - **Mechanism of Action**: MP0712 utilizes a DARPin vector linked to a radioisotope (Lead-212) to target DLL3 in small cell lung cancer. The approach aims to combine the efficacy of T cell engagers with the durability of antibody-drug conjugates (ADCs) [14][16][18] - **Clinical Strategy**: The company plans to initiate a phase one dose escalation trial, starting with a 75-megabecquerel dose, with a fast-to-market strategy for small cell lung cancer [27][30] Safety and Efficacy Considerations - **Safety Profile**: The rapid decay of Lead-212 is expected to result in minimal hematological toxicity, with recovery of blood values anticipated [34][37] - **Patient Experience**: Radiotherapy is expected to offer a better quality of life for patients compared to T cell engagers, which often cause acute side effects [37] Partnerships and Collaborations - **Orano Med Partnership**: A 50/50 partnership focused on the supply of Lead-212, with Orano Med providing a robust supply chain and infrastructure for the isotope [40][43] - **Future Collaborations**: The company is open to exploring partnerships for other isotopes, such as actinium, to enhance treatment options [45][46] Future Directions - **Expansion of Indications**: Beyond small cell lung cancer, there are plans to explore other neuroendocrine tumors with DLL3 expression [47][48] - **Innovative Imaging Techniques**: The use of imaging agents to select patients with DLL3 expression is seen as pivotal for maximizing treatment efficacy [48] Conclusion - **Focus for 2026**: The primary focus will be on MP0712, with expectations for first-in-human results and safety data in the first half of the year, followed by activity data in the second half [30]

I hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind drug development, which I now bring into my work as an investor and analyst. For the past five years, I have been active in the investing space, with the last four years dedicated to ...